肿瘤电场治疗联合标准全身治疗对比单纯标准全身治疗用于铂类治疗后进展的转移性非小细胞肺癌(LUNAR):一项随机、开放标签、关键性3期研究
这项在19个国家130个中心开展的随机开放标签3期研究纳入276例铂类治疗后进展的转移性非小细胞肺癌患者,按1:1随机接受肿瘤电场治疗(TTFields,150 kHz)联合标准全身治疗或单纯标准全身治疗。联合组中位总生存期显著长于单纯标准组(13.2个月 vs 9.9个月,HR 0.74,p=0.035)。
要点
- TTFields联合标准治疗较单纯标准治疗显著延长总生存期(中位13.2个月 vs 9.9个月,HR 0.74,p=0.035)。
- TTFields组53%报告任何原因的严重不良事件,单纯标准组为38%。
- TTFields相关不良事件95例(71%)多为1-2级皮肤及皮下组织疾病(81例,85%)。
核心结论
- 在铂类治疗后进展的转移性非小细胞肺癌中,TTFields联合标准治疗较单纯标准治疗显著改善总生存期,且未加重全身毒性。
- 作者认为TTFields在该人群中有效,应被考虑作为一种治疗选择。
研究设计与样本
- 随机、开放标签、关键性3期研究,在19个国家130个中心招募患者。
- 纳入年龄22岁及以上、铂类治疗后进展的转移性非小细胞肺癌患者,鳞状或非鳞状组织学,ECOG体能状态评分≤2。
- 按1:1随机分配至TTFields联合标准全身治疗组(n=137)或单纯标准全身治疗组(n=139),随机按组织学、治疗和地区分层。
- 标准全身治疗由研究者选择免疫检查点抑制剂(纳武利尤单抗、帕博利珠单抗或阿替利珠单抗)或多西他赛,按当地实践指南给药。
主要发现
- 2017年2月13日至2021年11月19日共入组276例患者,中位年龄64岁(IQR 59-70),男性178例(64%),女性98例(36%)。
- 非鳞状非小细胞肺癌156例(57%),既往接受过免疫检查点抑制剂者87例(32%)。
- TTFields联合标准组中位随访10.6个月(IQR 6.1-33.7),单纯标准组中位随访9.5个月(0.1-32.1)。
- 总生存期:TTFields联合标准组中位13.2个月(95%CI 10.3-15.5)vs 单纯标准组9.9个月(95%CI 8.1-11.5),HR 0.74(95%CI 0.56-0.98),p=0.035。
- 安全性人群(n=267)中,任何原因严重不良事件:TTFields联合标准组70/133(53%)vs 单纯标准组51/134(38%);最常见3-4级不良事件为白细胞减少37/267(14%)、肺炎28/267(10%)、贫血21/267(8%)。
关键数值与推荐
- TTFields治疗以150 kHz连续施加于胸部区域,建议平均每日设备使用至少18小时。
- 主要终点为意向治疗人群的总生存期。
- TTFields相关不良事件95/133(71%),其中81/95(85%)为1-2级皮肤及皮下组织疾病。
- 与标准治疗相关的死亡3例(2例感染,1例肺出血),无与TTFields相关的死亡。
临床怎么用
- 作者认为TTFields疗法在转移性非小细胞肺癌中有效,应被考虑作为该情形下管理疾病的一种治疗选择。
- 系统性治疗按当地实践指南给药,TTFields建议平均每日使用至少18小时。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tumor Treating Fields (TTFields) are electric fields that disrupt processes critical for cancer cell survival, leading to immunogenic cell death and enhanced antitumour immune response. In preclinical models of non-small-cell lung cancer, TTFields amplified the effects of chemotherapy and immune checkpoint inhibitors. We report primary results from a pivotal study of TTFields therapy in metastatic non-small-cell lung cancer. METHODS: This randomised, open-label, pivotal phase 3 study recruited patients at 130 sites in 19 countries. Participants were aged 22 years or older with metastatic non-small-cell lung cancer progressing on or after platinum-based therapy, with squamous or non-squamous histology and ECOG performance status of 2 or less. Previous platinum-based therapy was required, but no restriction was placed on the number or type of previous lines of systemic therapy. Participants were randomly assigned (1:1) to TTFields therapy and standard systemic therapy (investigator's choice of immune checkpoint inhibitor [nivolumab, pembrolizumab, or atezolizumab] or docetaxel) or standard therapy alone. Randomisation was performed centrally using variable blocked randomisation and an interactive voice-web response system, and was stratified by tumour histology, treatment, and region. Systemic therapies were dosed according to local practice guidelines. TTFields therapy (150 kHz) was delivered continuously to the thoracic region with the recommendation to achieve an average of at least 18 h/day device usage. The primary endpoint was overall survival in the intention-to-treat population. The safety population included all patients who received any study therapy and were analysed according to the actual treatment received. The study is registered with ClinicalTrials.gov, NCT02973789. FINDINGS: Between Feb 13, 2017, and Nov 19, 2021, 276 patients were enrolled and randomly assigned to receive TTFields therapy with standard therapy (n=137) or standard therapy alone (n=139). The median age was 64 years (IQR 59-70), 178 (64%) were male and 98 (36%) were female, 156 (57%) had non-squamous non-small-cell lung cancer, and 87 (32%) had received a previous immune checkpoint inhibitor. Median follow-up was 10·6 months (IQR 6·1-33·7) for patients receiving TTFields therapy with standard therapy, and 9·5 months (0·1-32·1) for patients receiving standard therapy. Overall survival was significantly longer with TTFields therapy and standard therapy than with standard therapy alone (median 13·2 months [95% CI 10·3-15·5] vs 9·9 months [8·1-11·5]; hazard ratio [HR] 0·74 [95% CI 0·56-0·98]; p=0·035). In the safety population (n=267), serious adverse events of any cause were reported in 70 (53%) of 133 patients receiving TTFields therapy plus standard therapy and 51 (38%) of 134 patients receiving standard therapy alone. The most frequent grade 3-4 adverse events were leukopenia (37 [14%] of 267), pneumonia (28 [10%]), and anaemia (21 [8%]). TTFields therapy-related adverse events were reported in 95 (71%) of 133 patients; these were mostly (81 [85%]) grade 1-2 skin and subcutaneous tissue disorders. There were three deaths related to standard therapy (two due to infections and one due to pulmonary haemorrhage) and no deaths related to TTFields therapy. INTERPRETATION: TTFields therapy added to standard therapy significantly improved overall survival compared with standard therapy alone in metastatic non-small-cell lung cancer after progression on platinum-based therapy without exacerbating systemic toxicities. These data suggest that TTFields therapy is efficacious in metastatic non-small-cell lung cancer and should be considered as a treatment option to manage the disease in this setting. FUNDING: Novocure.
引用
- Leal T, Kotecha R, Ramlau R, et al. Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study. Lancet Oncol. 2023. PMID: 37657460. doi:10.1016/S1470-2045(23)00344-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。